{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:23:52Z","timestamp":1794083032713,"version":"4.8.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet treatment for patients undergoing percutaneous coronary intervention (PCI) who are at both high bleeding and ischemic risk (birisk).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing DAPT with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in birisk patients with acute coronary syndromes (ACS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a multicenter, double-blind, placebo-controlled, randomized clinical trial including birisk patients with ACS who had completed 9 to 12 months of DAPT after drug-eluting stent implantation and were free from adverse events for at least 6 months at 101 China centers between February 2018 and December 2020. Study data were analyzed from April 2023 to May 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Patients were randomized either to clopidogrel plus placebo or clopidogrel plus aspirin for an additional 9 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end point was Bleeding Academic Research Consortium (BARC) types 2, 3, or 5 bleeding 9 months after randomization. The key secondary end point was major adverse cardiac and cerebral events (MACCE; the composite of all-cause death, myocardial infarction, stroke or clinically driven revascularization). The primary end point was tested for superiority, and the MACCE end point was tested for sequential noninferiority and superiority.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 7758 patients (mean [SD] age, 64.8 [9.0] years; 4575 male [59.0%]) were included in this study. The primary end point of BARC types 2, 3, or 5 bleeding occurred in 95 of 3873 patients (2.5%) assigned to clopidogrel plus placebo and 127 of 3885 patients (3.3%) assigned to clopidogrel plus aspirin (hazard ratio [HR], 0.75; 95% CI, 0.57-0.97; difference, \u22120.8%; 95% CI, \u22121.6% to \u22120.1%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.03). The incidence of MACCE was 2.6% (101 of 3873 patients) in the clopidogrel plus placebo group and 3.5% (136 of 3885 patients) in the clopidogrel plus aspirin group (HR, 0.74; 95% CI, 0.57-0.96; difference, \u22120.9%; 95% CI, \u22121.7% to \u22120.1%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001 for noninferiority;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.02 for superiority).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Among birisk patients with ACS who completed 9 to 12 months of DAPT after drug-eluting stent implantation and were free from adverse events for at least 6 months before randomization, an extended 9-month clopidogrel monotherapy regimen was superior to continuing DAPT with clopidogrel in reducing clinically relevant bleeding without increasing ischemic events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03431142\">NCT03431142<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2024.0534","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T11:10:12Z","timestamp":1713352212000},"page":"523","source":"Crossref","is-referenced-by-count":56,"title":["Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk"],"prefix":"10.1001","volume":"9","author":[{"given":"Yi","family":"Li","sequence":"first","affiliation":[{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanmin","family":"Jing","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zeng","sequence":"additional","affiliation":[{"name":"Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijie","family":"Hou","sequence":"additional","affiliation":[{"name":"The People\u2019s Hospital of Liaoning Province, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Wang","sequence":"additional","affiliation":[{"name":"Xinxiang Central Hospital, Xinxiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[{"name":"Benxi Central Hospital, Benxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Meihekou Central Hospital, Meiheko, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Xuzhou Third People\u2019s Hospital, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Tsinghua Changgung Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Dandong Central Hospital, Dandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[{"name":"The Second Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamao","family":"Fan","sequence":"additional","affiliation":[{"name":"Linfen Central Hospital, Linfen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cangzhou Central Hospital, Cangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Guangzhou Red Cross Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohai","family":"Su","sequence":"additional","affiliation":[{"name":"Central Hospital Affiliated to Shandong First Medical University, Ji\u2019nan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"Yingkou Central Hospital, Yingkou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Jiang","sequence":"additional","affiliation":[{"name":"The Third Xiangya Hospital of Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Qu","sequence":"additional","affiliation":[{"name":"The Second Hospital of Dalian Medical University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesong","family":"Zeng","sequence":"additional","affiliation":[{"name":"Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Shenyang Medical College, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaohan","family":"Qiu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leisheng","family":"Ru","sequence":"additional","affiliation":[{"name":"Bethune International Peace Hospital, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoliang","family":"Chen","sequence":"additional","affiliation":[{"name":"Nanjing First Hospital, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Qiao","sequence":"additional","affiliation":[{"name":"Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"University of Florida College of Medicine, Jacksonville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Han","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"OPT-BIRISK Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Gang","family":"Wu","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Yang","family":"Zheng","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Liyou","family":"Sui","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Jianbin","family":"Gong\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Jie","family":"Mi","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Ruiyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Xi","family":"Su\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Xingsheng","family":"Zhao\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Zhujun","family":"Chen\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Biao","family":"Xu","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Hanjun","family":"Pei\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Na","family":"Li\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Hongliang","family":"Cong","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Jinghua","family":"Liu","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Xiling","family":"Shou\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Fengde","family":"Wang\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Da","family":"Yin\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Xiaofeng","family":"Hu","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Jian","family":"An\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Chunyu","family":"Zeng","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Jincheng","family":"Guo\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Genshan","family":"Ma\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Xinfu","family":"Zhou","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Lefeng","family":"Wang\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Qin","family":"Qin","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Qiutang","family":"Zeng\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Shuangbin","family":"Li\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Yi","family":"Zheng","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Zuyi","family":"Yuan","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Qing","family":"Yang\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Gang","family":"Liu\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Xianxian","family":"Zhao","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Lingge","family":"Kong\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Jifu","family":"Li\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Tianchang","family":"Li\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Ruiping","family":"Zhao","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Chunjian","family":"Li\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Yanbo","family":"Jiang","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"\u00a0Likun","family":"Ma\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Ping","family":"Hou","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Zixin","family":"Zhang\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Junxia","family":"Li \u00a0\u00a0\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Zhixiong","family":"Zhong\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Zhimin","family":"Du \u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Zhiyong","family":"Wang\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Xuezhi","family":"Chen","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Longzhe","family":"Jin","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Changqian","family":"Wang","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Chengxing","family":"Shen","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Gang","family":"Zhao","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Xiaohui","family":"Liu","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Yongjun","family":"Li\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Chuanyu","family":"Gao\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Biao","family":"Cheng\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Jiang","family":"Wang","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Yuanzhe","family":"Jin\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Qun","family":"Jin","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Songjian","family":"He","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Zhaofen","family":"Zheng","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Yukun","family":"Luo","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Yingwu","family":"Liu \u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Taohong","family":"Hu","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Zhanying","family":"Han","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Weiheng","family":"Wu","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Hua","family":"Wang","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Yitong","family":"Ma","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Jianhong","family":"Tao","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Haiming","family":"Shi","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Fucheng","family":"Sun","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Yansong","family":"Guo","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Hongyi","family":"Wu\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Li","family":"Feng \u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Jianhua","family":"Zhu","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Xubo","family":"Shi","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Dr.","given":"Xiaodong","family":"Li\u00a0","sequence":"additional","affiliation":[{"name":"for the OPT-BIRISK Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"14","key":"hoi240013r1","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"hoi240013r2","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1161\/CIR.0000000000001039","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines.","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"hoi240013r3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization.","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"issue":"3","key":"hoi240013r4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC-focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"17","key":"hoi240013r5","doi-asserted-by":"publisher","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention.","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"issue":"1","key":"hoi240013r6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcin.2022.10.023","article-title":"Timing, selection, modulation, and duration of P2Y12 inhibitors for patients with acute coronary syndromes undergoing PCI.","volume":"16","author":"Capodanno","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"hoi240013r7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41569-022-00725-6","article-title":"P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"hoi240013r8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention.","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"hoi240013r9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions.","volume":"81","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi240013r10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial.","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"10127","key":"hoi240013r11","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-Month vs 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomized, open-label, noninferiority trial.","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"hoi240013r12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1161\/CIRCULATIONAHA.122.063004","article-title":"Long-term P2Y12 inhibitor or aspirin as single antiplatelet therapy in patients with previous percutaneous coronary intervention.","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"hoi240013r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2020.07.005","article-title":"Extended antiplatelet therapy with clopidogrel alone vs clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk\u2014rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.","volume":"228","author":"Li","year":"2020","journal-title":"Am Heart J"},{"issue":"23","key":"hoi240013r14","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"23","key":"hoi240013r15","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1093\/eurheartj\/ehy223","article-title":"Standardized end point definitions for coronary intervention trials: the Academic Research Consortium 2 consensus document.","volume":"39","author":"Garcia-Garcia","year":"2018","journal-title":"Eur Heart J"},{"issue":"23","key":"hoi240013r16","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"hoi240013r17","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI.","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"hoi240013r18","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual Antiplatelet Therapy after PCI in patients at high bleeding risk.","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi240013r19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"},{"issue":"7","key":"hoi240013r20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/ehjcvp\/pvac020","article-title":"Extended, standard, or de-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention: a trial-sequential, bivariate, influential, and network meta-analysis.","volume":"8","author":"Ullah","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1332","key":"hoi240013r21","doi-asserted-by":"publisher","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularization: individual patient level meta-analysis of randomised controlled trials.","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"key":"hoi240013r22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ahj.2019.10.001","article-title":"Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: insights from the BleeMACS and RENAMI registries.","volume":"220","author":"D\u2019Ascenzo","year":"2020","journal-title":"Am Heart J"},{"key":"hoi240013r23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/ccd.v95.S1","article-title":"Impact of dual antiplatelet therapy duration on 1-year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the real-world OPT-CAD study.","volume":"95","author":"Li","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"hoi240013r24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.scib.2018.12.020","article-title":"2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.","volume":"64","author":"Huo","year":"2019","journal-title":"Sci Bull (Beijing)"},{"issue":"5","key":"hoi240013r25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jjcc.2019.11.003","article-title":"Ticagrelor vs clopidogrel in acute myocardial infarction patients with multivessel disease; from Korea Acute Myocardial Infarction Registry\u2014National Institute of Health.","volume":"75","author":"Ahn","year":"2020","journal-title":"J Cardiol"},{"issue":"8","key":"hoi240013r26","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1080\/09537104.2022.2118250","article-title":"Clopidogrel vs ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry.","volume":"33","author":"Xi","year":"2022","journal-title":"Platelets"},{"issue":"17","key":"hoi240013r27","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.4103\/0366-6999.239306","article-title":"Impact of baseline bleeding risk on efficacy and safety of ticagrelor vs clopidogrel in chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention.","volume":"131","author":"Wang","year":"2018","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"hoi240013r28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/HCO.0000000000000792","article-title":"Adverse events beyond 1 year after percutaneous coronary intervention.","volume":"35","author":"Madhavan","year":"2020","journal-title":"Curr Opin Cardiol"},{"issue":"19","key":"hoi240013r29","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction.","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"hoi240013r30","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.120.046308","article-title":"Dual Antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis.","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"hoi240013r31","doi-asserted-by":"publisher","first-page":"l2222","DOI":"10.1136\/bmj.l2222","article-title":"Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis.","volume":"365","author":"Yin","year":"2019","journal-title":"BMJ"},{"issue":"9038","key":"hoi240013r32","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomized, blinded, trial of clopidogrel vs aspirin in patients at risk of ischaemic events (CAPRIE).","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"issue":"10293","key":"hoi240013r33","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin vs clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicenter trial.","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"hoi240013r34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1161\/CIRCULATIONAHA.122.062770","article-title":"Aspirin vs clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study.","volume":"147","author":"Kang","year":"2023","journal-title":"Circulation"},{"issue":"24","key":"hoi240013r35","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016495","article-title":"Pharmacodynamic comparison of ticagrelor monotherapy vs ticagrelor and aspirin in patients after percutaneous coronary intervention: the TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) randomized controlled trial.","volume":"9","author":"Johnson","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"hoi240013r36","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jacc.2019.11.056","article-title":"Ticagrelor with or without aspirin after PCI: the TWILIGHT platelet substudy.","volume":"75","author":"Baber","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"hoi240013r37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jacc.2021.10.028","article-title":"Magnetically controlled capsule endoscopy for assessment of antiplatelet therapy-induced gastrointestinal injury.","volume":"79","author":"Han","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"hoi240013r38","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1111\/jgh.v35.10","article-title":"Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting.","volume":"35","author":"Tang","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"hoi240013r39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events.","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hoi240013r40","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/jamacardio.2022.3203","article-title":"Long-term effects of P2Y12 inhibitor monotherapy after percutaneous coronary intervention: 3-year follow-up of the SMART-CHOICE randomized clinical trial.","volume":"7","author":"Choi","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"8","key":"hoi240013r41","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"issue":"8","key":"hoi240013r42","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jcin.2022.01.300","article-title":"Dual antiplatelet therapy discontinuation, platelet reactivity, and adverse outcomes after successful percutaneous coronary intervention.","volume":"15","author":"Redfors","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"16","key":"hoi240013r43","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.jacc.2017.02.029","article-title":"Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting.","volume":"69","author":"Palmerini","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10073","key":"hoi240013r44","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"issue":"31","key":"hoi240013r45","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"hoi240013r46","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1201091","article-title":"Effect of dual antiplatelet therapy prolongation in acute coronary syndrome patients with both high ischemic and bleeding risk: insight from the OPT-CAD study.","volume":"10","author":"Na","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"22","key":"hoi240013r47","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1016\/j.jcin.2022.09.046","article-title":"Platelet reactivity testing: East meets West.","volume":"15","author":"Stone","year":"2022","journal-title":"JACC Cardiovasc Interv"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2817471\/jamacardiology_li_2024_oi_240013_1718026038.85733.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T11:01:48Z","timestamp":1718190108000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2817471"}},"subtitle":["The OPT-BIRISK Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.0534","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}